Biomerica Inc. Files Definitive Additional Materials Proxy Statement
Ticker: BMRA · Form: DEFA14A · Filed: Oct 23, 2025 · CIK: 73290
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
BIOMERICA files proxy docs, shareholder vote incoming.
AI Summary
Biomerica Inc. filed a Definitive Additional Materials proxy statement on October 23, 2025. The filing pertains to matters requiring shareholder approval, as indicated by the DEFA14A form type. Specific details regarding the proposals or resolutions are not provided in this excerpt.
Why It Matters
This filing indicates that Biomerica Inc. is seeking shareholder input or approval on important corporate matters, which could impact the company's future direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is a standard proxy statement, indicating routine corporate governance activities rather than immediate financial distress or significant operational changes.
Key Players & Entities
- BIOMERICA INC (company) — Registrant
- 0001493152-25-019081 (filing_id) — Accession Number
- 20251023 (date) — Filing Date
- 17571 VON KARMAN AVENUE (address) — Business Address
- IRVINE (city) — Business Address City
- CA (state) — Business Address State
- 92614 (zip_code) — Business Address Zip
- 9493792875 (phone_number) — Business Phone
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Materials proxy statement filed by Biomerica Inc. under Schedule 14A, indicating it contains materials provided to shareholders in connection with a shareholder meeting or vote.
When was this filing submitted to the SEC?
The filing was submitted on October 23, 2025.
What is Biomerica Inc.'s primary business classification?
Biomerica Inc. is classified under the Standard Industrial Classification code 2835, which pertains to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Where is Biomerica Inc. located?
Biomerica Inc.'s business address is 17571 Von Karman Avenue, Irvine, CA 92614.
Has Biomerica Inc. operated under different names previously?
Yes, Biomerica Inc. was formerly known as NMS Pharmaceuticals Inc. (name change in 1987), Nuclear Medical Systems Inc. (name change in 1983), and Nuclear Instruments Inc. (name change in 1972).
Filing Stats: 246 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2025-10-23 16:15:04
Filing Documents
- formdefa14a.htm (DEFA14A) — 28KB
- notice_001.jpg (GRAPHIC) — 408KB
- notice_002.jpg (GRAPHIC) — 164KB
- 0001493152-25-019081.txt ( ) — 817KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 BIOMERICA, INC. (Name of Registrant as Specified in Its Charter) N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration (3) Filing Party: (4) Date Filed